2 years ago
IONS
AnalystsAkash TewariAkash Tewari's Stock Forecasts
AnalystsAkash Tewari
Analyst Ranking
Top 34%
#1727 out of 5209 analysts
Average Return
+2.12%
Win Rate
37%19 out of 51
Risk vs Reward
Poor
Good
Akash Tewari's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | +203.14% | $14.03 | $42.53 | 2025-11-02 - 2026-03-04 | Strong Buy |
Global Blood Therapeutics IncGBT | +139.48% | $27.81 | $66.60 | 2021-10-06 - 2022-08-08 | Strong Buy |
Apogee Therapeutics IncAPGE | +90.45% | $21.46 | $40.87 | 2023-08-07 - 2024-08-07 | Strong Buy |
Apogee Therapeutics IncAPGE | +90.45% | $21.46 | $40.87 | 2023-08-07 - 2024-08-07 | Strong Buy |
Cytokinetics IncCYTK | +64.33% | $22.82 | $37.50 | 2021-03-11 - 2022-03-11 | Buy |
Akash Tewari Analyst Color
Get additional color on Akash Tewari's coverage of popular stocks
2 years ago
LLY
2 years ago
LLY
2 years ago
APGE
2 years ago
APLS
2 years ago
PFE
3 years ago
LLY
3 years ago
LLY
3 years ago
LLY
3 years ago
PFE
3 years ago
ZYME
3 years ago
BMRN
4 years ago
BNTX
Akash Tewari's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | 2 | Strong Buy | $35.00 | -17.71% | Maintains | 4 months ago |
Ionis Pharmaceuticals IncIONS | 2 | Strong Buy | $96.00 | +20.85% | Maintains | 6 months ago |
Regeneron Pharmaceuticals IncREGN | 5 | Strong Buy | $831.00 | +5.52% | Maintains | 6 months ago |
Crescent Biopharma IncCBIO | 1 | Strong Buy | $26.00 | +126.28% | Initiates Coverage On | 6 months ago |
Arvinas IncARVN | 3 | Hold | $10.00 | -27.33% | Downgrades | 10 months ago |
Bristol Myers Squibb CoBMY | 4 | Strong Buy | $68.00 | +9.10% | Maintains | 10 months ago |
Biomarin Pharmaceutical IncBMRN | 2 | Buy | $95.00 | N/A | Initiates Coverage On | a year ago |
Biontech SeBNTX | 3 | Strong Buy | $150.00 | N/A | Upgrades | a year ago |
Relay Therapeutics IncRLAY | 3 | Strong Buy | $16.00 | N/A | Upgrades | a year ago |
Neurocrine Biosciences IncNBIX | 2 | Strong Buy | $189.00 | N/A | Maintains | 2 years ago |
Apellis Pharmaceuticals IncAPLS | 2 | Strong Buy | $80.00 | N/A | Maintains | 2 years ago |
Eli Lilly & CoLLY | 6 | Strong Buy | $1,015.00 | N/A | Maintains | 2 years ago |
Alkermes PLCALKS | 2 | Strong Buy | $50.00 | N/A | Maintains | 2 years ago |
Apogee Therapeutics IncAPGE | 4 | Strong Buy | $75.00 | N/A | Maintains | 2 years ago |
Spyre Therapeutics IncSYRE | 1 | Strong Buy | $31.00 | N/A | Initiates Coverage On | 2 years ago |
Acelyrin IncSLRN | 2 | Strong Buy | $12.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 2 | Strong Buy | $39.00 | N/A | Upgrades | 2 years ago |
Enanta Pharmaceuticals IncENTA | 2 | Hold | $18.00 | N/A | Downgrades | 3 years ago |
Argenx SeARGX | 2 | Strong Buy | $513.00 | N/A | Maintains | 3 years ago |
Merck & Co IncMRK | 1 | Strong Buy | $125.00 | N/A | Initiates Coverage On | 3 years ago |
Zymeworks IncZYME | 1 | Strong Buy | $11.00 | N/A | Upgrades | 3 years ago |
Third Harmonic Bio IncTHRD | 2 | Hold | $3.60 | N/A | Downgrades | 3 years ago |
Acrivon Therapeutics IncACRV | 1 | Strong Buy | $17.00 | N/A | Initiates Coverage On | 3 years ago |
Eqrx IncEQRX | 2 | Hold | $3.20 | N/A | Downgrades | 3 years ago |
Global Blood Therapeutics IncGBT | 3 | Hold | $68.50 | N/A | Downgrades | 4 years ago |
Cytokinetics IncCYTK | 2 | Strong Buy | $75.00 | N/A | Initiates Coverage On | 4 years ago |
Madrigal Pharmaceuticals IncMDGL | 1 | Strong Buy | $151.00 | N/A | Initiates Coverage On | 4 years ago |
Exelixis IncEXEL | 2 | Strong Buy | $28.00 | N/A | Initiates Coverage On | 4 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $180.00 | N/A | Initiates Coverage On | 4 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 1 | Buy | $107.00 | N/A | Initiates Coverage On | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.